Orexigen (OREX) Surges On 'Aggressive' Buy Calls Ahead of Catalysts
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Credit Suisse Starts Orexigen Therapeutics (OREX) at Outperform
September 5, 2012 5:18 PM EDTAfter the close, Credit Suisse initiated coverage on Orexigen Therapeutics (NASDAQ: OREX) with a Outperform. PT $13.00.
For an analyst ratings summary and ratings history on Orexigen Therapeutics click here. For more ratings news on... More
Orexigen (OREX) Enrollment in Light Study Continues Faster than Anticipated, Sees Closing in Q412
September 5, 2012 6:32 AM EDTOrexigen Therapeutics, Inc. (Nasdaq: OREX) today announced an update to the projected timeframe for enrollment of patients in the Light Study, the cardiovascular outcomes clinical trial evaluating Contrave® (naltrexone SR/ bupropion SR). Enrollment into the study has continued without abatement at a rate faster than originally expected, with more than 4,500 patients enrolled as... More
